Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI® (brensocatib) Revenues of $400.1 Million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results